Center for the Biology of Chronic Disease (CBCD)

Age Increases the Danger of Shingles According to an Extensive Scientific Review

In addition, the elderly who develop HZ (shingles) often have underlying diseases and are at increased risk of disability. (1)

 

Rochester, NY -- (SBWIRE) -- 09/28/2015 -- "Infected with the varicella zoster virus (VZV), which causes shingles? The Center for the Biology of Chronic Disease (CBCD) recommends taking Gene-Eden-VIR" - Greg Bennett, CBCD

Herpes Zoster (HZ), commonly called shingles, is a distinctive syndrome caused by reactivation of varicella zoster virus (VZV), which also causes chickenpox. VZV is a herpes virus. A review of the scientific literature published in BMC Public Health found that people throughout Europe develop shingles more often as they age. (1) Dr. Bricout and colleagues wrote that "This review confirmed that, in Europe, HZ incidence increases with age, particularly after 50 years of age. Similarly, data on the percentage of HZ cases who develop PHN are available across EU. PHN, defined as HZ-associated pain lasting for at least three months, has been reported to occur in 10% to 20% of patients. However, the prevalence and severity of PHN increases with age, and has been reported to be as high as 60% to 70% of patients aged ?60 (over 60). In people aged over 50 years, there is a higher rate of HZ-associated hospitalization and HZ and PHN have a greater impact on the quality of life of patients and their relatives." (1) In other words, the older a person gets, the more dangerous the virus becomes. That is, the older a person, the more likely the person can die from the infection.

In the same review of the medical literature, scientists found that in addition to in severity of the disease, death rates also increase with age. Dr. Bricout and colleagues wrote that "the HZ mortality (death) rate varied by gender and was generally higher in women." (1) Interestingly, the scientists found that in certain countries, men had higher HZ mortality rates. These countries included Spain, Italy, France, and Denmark. Dr. Bricout and colleagues are from the Epidemiology Departmental Sanofi Pasteur MSD, in France.

The Center for the Biology of Chronic Disease (CBCD) recommends that individuals who have ever had chickenpox take Gene-Eden-VIR. The formula of this natural antiviral product was shown to reduce symptoms associated with herpes viruses.

Click to learn more about the shingles virus.

The Gene-Eden-VIR formula was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the formula is effective against the herpes family of viruses. Varicella Zoster is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the (herpes viruses) … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (2) The study authors also wrote that, "we observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (2)

Gene-Eden-VIR can be ordered from the product's website here:

http://www.gene-eden-vir.com

Gene-Eden-VIR is a natural antiviral dietary supplement. Its formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Gene-Eden-VIR is the only natural antiviral product on the market with a formula published in clinical studies that support its claims.

"… data from the US, for 1979 to 2007, showed that the HZ mortality rate was higher in older patients … mortality rates were higher when HZ was reported to be an associated or secondary cause of death suggesting that the HZ episode could have an indirect role in mortality … it has been estimated that the risk of dying was five-times higher within three years of HZ reactivation." (1)

The CDC notes that the varicella zoster virus (VZV), which is a herpes virus, causes both chickenpox and shingles. "After a person recovers from chickenpox, the virus stays dormant (inactive) in the body. For reasons that are not fully known, the virus can reactivate years later, causing shingles." (3) Additionally, the CDC adds that "almost 1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. There are an estimated 1 million cases of shingles each year in this country. Anyone who has recovered from chickenpox may develop shingles; even children can get shingles. However the risk of shingles increases as you get older. About half of all cases occur in men and women 60 years old or older." (3)

Are there treatments currently on the market, which target the Varicella Zoster Virus (VZV)?

Yes there are.

Antiviral drugs, such as Zovirax or Valtrex are designed to fight the shingles virus. However, these medications, when effective, only work to shorten the time of the shingles outbreak. They are ineffective against the latent VZV virus. (3)

In contrast, Gene-Eden-VIR has an antiviral formula designed to target the latent VZV (shingles virus).

"We recommend that older individuals take Gene-Eden-VIR against the latent VZV. The formula of this natural antiviral products was designed to help the immune system target the virus in its latent form." – Greg Bennett, CBCD

Find us on Facebook here: https://www.facebook.com/GeneEdenVIR
Follow us Twitter here: @HananPolansky

All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Bricout H1, Haugh M2, Olatunde O3, Gil Prieto R4. "Herpes zoster-associated mortality in Europe: a systematic review." BMC Public Health. 2015 May 5;15(1):466.

http://www.ncbi.nlm.nih.gov/pubmed/25940080

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101

(3) CDC.gov - "Shingles (Herpes Zoster)" - Prevention & Treatment. Last Reviewed on May 1, 2014.

http://www.cdc.gov/shingles/about/prevention-treatment.html

About The Center for the Biology of Chronic Disease
The Center for the Biology of Chronic Disease (CBCD, http://www.cbcd.net) is a research center recognized by the IRS as a 501(c)(3) non-for-profit organization. The mission of the CBCD is to advance the research on the biology of chronic diseases, and to accelerate the discovery of treatments for these diseases.